antipsychotic | CARLAT PUBLISHING

Psychopharm Commandment 7A: Red Flags & Controlled Meds

April 3, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

The DEA has warned pharmacists to watch for Red Flags in controlled prescriptions, and we’ll show you what they are and how to use them therapeutically in practice.

Clinical Update

Confused About Acute Confusional States? A Primer on Delirium

April 1, 2023

Michael Strong, MD and Alexander Thompson, MD, MBA, MPH

Michael Strong, MD. Assistant professor of clinical psychiatry, Perelman School of Medicine at the University of Pennsylvania. Philadelphia, PA.
Alexander Thompson, MD, MBA, MPH. Clinical professor of psychiatry and emergency medicine; director, C-L Psychiatry, University of Iowa. Iowa City, IA.
Dr. Strong and Dr. Thompson have no financial relationships with companies related to this material.

Delirium is widespread among patients in ICUs and surgery units. We review the workup and management of this common condition and give you tips to help prevent it in high-risk patients.

SAINT TMS Cleared for Treatment-Resistant Depression

September 12, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

Clinical Update

Treatment of Antipsychotic-Induced Weight Gain

September 1, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association.

Dr. Miller, author of this educational activity, receives research support from Augusta University; the National Institute of Mental Health; the Brain and Behavior Research Foundation; and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

From lifestyle changes to liraglutide, Brian Miller details best practices for managing this insidious side effect.

Medication Management of Antipsychotic-Induced Weight Gain in Children and Teens

July 25, 2022

Joshua Feder, MD and Mara Goverman

Second-generation antipsychotics routinely breach the FDA’s level of concern of >7% body weight gain. This article examines the efficacy and safety of using off-label medications, such as metformin, to manage this side effect.

RESEARCH UPDATE

Antipsychotics for Methamphetamine Psychosis

January 18, 2022

Sanya Virani, MD.

Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this network meta-analysis, researchers compared different antipsychotics head-to-head for the treatment of methamphetamine psychosis and found some clear winners are losers.

Combination Treatment for Schizophrenia

April 12, 2021

T. Scott Stroup, MD, MPH

T. Scott Stroup, MD, MPH
Professor of Psychiatry, Columbia University, NY. Dr. Stroup has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. T. Scott Stroup, Professor of Psychiatry at Columbia University, reveals surprising findings from his research on the use of adjunctive medications for schizophrenia.

An Antipsychotic Patch

November 15, 2019

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Secuado, the first transdermal patch for schizophrenia, is newly approved version of asenapine (aka Saphris). It promises to reduce side effects and enhance adherence. However, it adds a new side effect of its own, and transdermal delivery isn’t clearly better than sublingual, which is how the older Saphris is absorbed.